A-86929
A-86929 is a synthetic compound that acts as a potent and selective dopamine receptor agonist. It was developed by a team of researchers at Abbott Laboratories in the 1990s. A-86929 has been used in scientific research to better understand the role of dopamine receptors in the brain and their potential implications for treating neurological and psychiatric disorders.
Chemistry[edit | edit source]
A-86929 is a member of the benzazepine class of compounds. It is structurally similar to other dopamine agonists such as fenoldopam and SKF-38393, but it is distinguished by its unique substitution pattern on the benzazepine ring. This structural feature is believed to contribute to its high potency and selectivity for dopamine receptors.
Pharmacology[edit | edit source]
A-86929 acts as a full agonist at both D1 and D2 subtypes of dopamine receptors. It has a high affinity for these receptors, which means it can bind to them and activate them very effectively. This makes A-86929 a valuable tool for studying the function of dopamine receptors in the brain.
Clinical significance[edit | edit source]
While A-86929 itself has not been developed as a therapeutic drug, it has been used as a lead compound in the development of other drugs. Most notably, it served as the basis for the design of apomorphine, a drug that is currently used to treat the motor symptoms of Parkinson's disease.
See also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD